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Strange, but true -- in America, only the incar-
cerated have a legal right to healthcare.  This
right stems from early recognition by the courts
that, "the public be required to care for the pris-
oner, who cannot by reason of the deprivation
of his liberty, care for himself." Spicer v.
Williams, 191 N.C. 487 (1926). However, the
Supreme Court did not formally recognize an
inmate’s constitutional right to healthcare until
1976, when the court established that "deliber-
ate indifference to serious medical needs of
prisoners" is a violation of the Eighth
Amendment. This article discusses the Eighth
Amendment right of incarcerated persons to
medical care and examines that right in the con-
text of inmates with HIV disease.
The Constitutional Basis of
the Right
The right of the convicted inmate to medical
care comes from the Eighth Amendment’s pro-
hibition on "cruel and unusual punishments."
Although originally intended to prevent "tortures
and other barbarous forms of punishment," the
clause has been interpreted by the Supreme
Court to include a right to medical treatment for
convicted inmates that does not allow "wanton
and willful infliction of pain."  
Pre-trial detainees also have a right to health-
care, under the Fourteenth Amendment, which
prohibits the government’s denial of "life, liberty
or property without due process of law."
Although the pre and post-conviction rights
come from separate constitutional provisions,
the Supreme Court has never articulated the
due process medical care standard, and the
rights have been interpreted by the courts to
require the same level of treatment.   Revere v.
Massachusetts Gen. Hosp., 463 U.S. 239, 244
(1983). 
A Historic Case: 
Estelle v. Gamble (1976)
In Estelle v. Gamble, 429 U.S. 97 (1976), the
Supreme Court addressed the medical needs of
prisoners in the context of the Eighth
Amendment.  
The court held that deliberate indifference to
serious medical needs is prohibited whether
the indifference is manifested by prison doctors
in their response to the prisoner’s needs or by
prison guards in intentionally denying or delay-
ing access to medical care or intentionally inter-
fering with the treatment once prescribed.
Regardless of how evidenced, deliberate indif-
ference to a prisoner’s serious illness or injury
states a [claim under the Constitution.] Id. at
104-105."
Note that both providers and correctional offi-
cers might, according to this interpretation of
the Eighth Amendment, be held to be responsi-
ble if an HIV-infected patient failed to receive
their HIV medications. However, a prisoner
must provide evidence of "acts or omissions
sufficiently harmful" to show deliberate indiffer-
ence in order to bring an Eighth Amendment
claim.  
Since Estelle, the Supreme Court has only
refined the "deliberate indifference" standard
once.  In 1994 the Court said that deliberate
indifference ". . . [lies] somewhere between the
poles of negligence at one end and purpose or
knowledge at the other,"(Farmer v. Brennan,
511 U.S. 825, 1994). The Court affirmed an
"adequacy" standard stating that  ". . . prison
officials must ensure that inmates receive ade-
quate food, clothing, shelter and medical care .
. ." (id. at 833), but went on to emphasize that
"deliberate indifference" requires a culpable
state of mind. Federal District Courts (the trial
court in the Federal system) may interpret "ade-
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quate" with wide discretion.  On appeal to
the Federal Circuit Courts-the layer of the
judiciary just below the US Supreme Court-
this has led to vastly varying law, especial-
ly in regards to the treatment of HIV.
Recent decisions in HIV
Cases
Circuit Courts
The best way to find out how "deliberate
indifference" is being interpreted in relation
to HIV treatment in correctional settings is
to look at recent court rulings. Only two cir-
cuit courts (the regional federal appellate
courts directly below the Supreme Court)
have considered treatment of HIV disease
and the Eighth Amendment since the
development of protease inhibitors, with
drastically different results.   
In Perkins v. Kansas Dept. of Corrections,
165 F.3d 803 (10th Cir. 1999) the
patient/inmate challenged his HIV treat-
ment which, in February 1998, consisted of
AZT and 3TC, but not a protease inhibitor.
The Tenth Circuit, while noting the patient’s
argument that "HIV will become immune to
[AZT and 3TC] if he is not given a protease
inhibitor," and footnoting the important role
protease inhibitors play in the treatment of
HIV disease, held " . . . prison officials have
recognized his serious medical condition
and are treating it.  Plaintiff simply dis-
agrees with medical staff about the treat-
ment.  This disagreement does not give rise
to a claim for deliberate indifference to seri-
ous medical needs."  Thus, despite good
scientific data to the contrary that was
available at the time, the Tenth Circuit held
that denial of one component of combina-
tion therapy is simply a "disagreement"
about appropriate treatment.
By contrast, the Ninth Circuit has held that
denial of the full combination for two days
creates a triable issue of whether the med-
ical staff was "deliberately indifferent" to the
patient/inmate’s medical needs.  Sullivan v.
County of Pierce, 2000 U.S. App. LEXIS
8254 (9th Cir. 2000) In Sullivan, the
patient/inmate did not receive his protease
inhibitor because the jail pharmacy did not
stock the medication, despite the fact that
the medical staff testified that is was "com-
mon medical knowledge that an AIDS
patient taking protease inhibitors as part of
an AIDS cocktail had to remain in strict
compliance with that regimen at all times
and without exception lest that cocktail
become ineffective."  The Ninth Circuit said
that, "[a]lthough jail physicians, like prison
officials, enjoy wide discretion in determin-
ing what constitutes appropriate treatment,
the treatment Sullivan received was far
from the medical norm. . . . " Accordingly,
the court concluded that the jail was guilty
of deliberate indifference.
District Courts
Based on the written opinions of the last
several years, district court judges appear
to be more willing to let HIV treatment-relat-
ed claims go forward to trial, by no means
guaranteeing victory, but allowing
inmate/patients to have their claims heard
by a jury. With two such polar opinions by
the Circuit Courts, it is no wonder that
District Courts are not uniform in their
approach to HIV care. For instance, one
Maine court held that three days in a jail
without medications was sufficient cause
for a jury to decide whether that was delib-
erate indifference (McNally v. Prison Health
Services, 46 F.Supp.2d 49. Dist. Ct. Maine,
1999).  A Virginia District Court held like-
wise when an inmate’s medications were
changed without his notification and he suf-
fered side effects (Taylor v. Barnett, 105
F.Supp2d 483. E.Dist. Va. 2000).  An Illinois
case is particularly notable because of the
inmate’s persistence in requesting medica-
tions. After notifying repeatedly that she
needed HIV medications, yet going without
them for two weeks, the inmate was found
comatose in her cell.  In that case, the court
held that the medical staff was not deliber-
ately indifferent, and the claim was denied
(Rivera v Sheehan 1998 US District LEXIS
12880 N. Dist Ill 1998).
On the other hand, a New York Federal
Court this year held that a Spanish-speak-
ing only inmate, who missed his medica-
tions because the instructions to pick up his
medications were printed in English, did not
suffer deliberate indifference even though it
resulted in a worsening of his condition
(Leon v. Johnson, 96 F. Supp. 2d 244.
WDNY 2000).  Earlier, in 1997, in New York
the court held the prison system was not
deliberately indifferent when an inmate was
off medications for a period of a week dur-
ing transport between facilities.  Again,
these decisions may have turned on
whether or not the providers of medication
had a "culpable state of mind." As knowl-
edge of HIV management becomes more
widespread, court rulings on events such
as those described in this paragraph may
evolve (Nolley v. Johnson, 1997 U.S. Dist.
LEXIS 17651. S.D.N.Y. 1997).
No resolution: Alabama
and the Supreme Court
One reason the Supreme Court takes
cases is to settle differing opinions of
Federal Circuit Courts of Appeals. It has not
done so in this area. A district court judge in
the Eleventh Circuit recently held that
prison officials could not be held liable for
damages for a delay in delivering HIV med-
ications of three or four days.  Edwards v.
Alabama Dept. of Corrections, 81 F. Supp.
2d 1242 (Mid. Dist Ala. 2000).  That court’s
decision was based in large part on the
controlling precedent set by  the Eleventh
Circuit on facts developed ten years earlier
in Harris v. Thigpen, 941 F.2d 1495 (11th
Cir. 1991). In the late 1980s, when the
treatment of HIV disease was dramatically
different the Eleventh Circuit held that the
care for HIV in Alabama, although poor,
was adequate for Alabama prisoners
because of the changing nature of the
treatment of the disease and poor state of
health care available to the non-incarcerat-
ed in Alabama.  
Thus, the district court in Edwards, was
forced to conclude that prison officials
could not be held liable for damages due to
the final rulings in the Harris case. Under a
legal defense called "qualified immunity"
state actors are immune from liability for
their discretionary acts unless they violate
"clearly established statutory or constitu-
tional rights of which a reasonable person
would have known."   Therefore, based on
the Eleventh Circuit’s 1987 decision in
Harris - the Alabama DOC could reason-
ably believe they were, and are, operating
a constitutionally adequate medical sys-
tem, and are not liable for damages.   
Conclusion
By no means a black and white rule, the
"deliberate indifference" standard of Eighth
Amendment jurisprudence gives judges
wide latitude to determine the standard of
medical care owed to incarcerated individ-
uals, and, unfortunately, leaves correction-
al medical providers and inmate/patients
without strict guidance.  
Due to the fast pace at which HIV treatment
changes, it is particularly difficult to deter-
mine what constitutes "deliberate indiffer-
ence" in this area. Some courts are satis-
fied if inmates have access to some HIV
care, even if out of date; others will exam-
ine a doctor’s decision to change an indi-
vidual inmate/patient’s medical regimen.
The Supreme Court is unlikely to resolve
the divergence of opinions that currently
exist among lower courts anytime in the
near future. Since judicial process has thus
far failed to provide a clear standard
regarding the management of HIV disease
in correctional settings, decisions regarding
care remain largely in the hands of medical
care providers who care for the incarcerat-
ed patient.
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Dear Colleagues,
Thanksgiving is upon us, and those of us providing care to HIV-infected prisoners certainly
have much to be thankful for. New treatments have led to declining death rates from oppor-
tunistic infections and cancers. Inmate initiated litigation has in some cases led to neces-
sary changes in the provision of healthcare to the incarcerated. Slowly, there is a growing
realization that the health status of prisoners affects us all, and that better linkages must be
in place to provide health care to this population as it moves back and forth between
jail/prison and the free world. And in California, a ballot initiative has just been passed that
is intended to place a greater emphasis on treatment rather than incarceration for many of
those arrested for substance abuse related crimes.  
These hopeful signs are tempered by some chilling realities. An increasing prevalence of
resistant HIV is leading to treatment failures. Shrinking budgets and lack of vision have hin-
dered effective treatment partnerships. New restrictions on inmate litigation have limited the
role of the courts in improving inmate health care. And worldwide, many HIV-infected pris-
oners still face conditions that are tantamount to a death sentence.
This month, Mary Sylla and David Thomas provide an overview of Law and AIDS in
Corrections.  Yet to be seen is whether the courts will provide a national standard for HIV
care in prisons, or whether clinicians will be left to define this facility by facility.
Rick Altice provides an approach to the initiation of antiretroviral therapy in a treatment naïve
inmate, and the HIV 101 provides an HIV drug update.
After reviewing this month’s issue, readers should be able to identify appropriate ART regi-
mens for treatment-naïve patients;  know more about the use of the new lopinavir/ritonavir
combination, Kaletra; list the responsibilities of prison officials for medical care according to
US law; and understand the latest developments concerning opportunistic infections in HIV
patients.
As we gather with our loved ones this year and give thanks for all of our blessings, let us
not forget all that remains to be done in our struggle to improve the health care of those that
society has entrusted to us. 
Sincerely,
Joseph Bick, M.D.
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ZIDOVUDINE
(AZT, ADV, Retrovir)
100 and 300mg tabs
IV vials-10mg/ml
300mg/3TC 150mg
as Combivir
10mg/mL oral soln
300mg bid (or with
3TC as Combivir 1
tab bid)
None
G Bone Marrow
suppression: anemia
and/or neutropenia
G subjective com-
plaints: GI intoler-
ance, headache, 
insomnia, asthenia
Ribavirin may
reduce AZT activity
DIDANOSINE
(ddl, Videx)
25, 50, 100 and
150mg tabs; 100,
167 and 250 mg
powder packets
200mg tabs for 
once daily dosing
Tablets or oral soln
>60kg: 400mg qd or
200mg bid (tabs) or
250mg bid (powder) 
<60kg: 250mg qd or
125mg bid (tabs) or
167mg bid (powder)
Levels  $55% Take
1 hr before or 1 hr
after meal
G Pancreatitis
G Peripheral 
neuropathy
G GI intolerance,
nausea, diarrhea
Methadone$ ddI 
levels 41%, consider
ddI dose increase
ZALCITABINE
(ddC, Hivid)
0.375 and 0.75mg
tabs
0.75mg tid
None
G Peripheral 
neuropathy
G Stomatitis
Methadone$ ddC 
levels 27%.  No
dose adjustment
STAVUDINE
(d4T, Zerit)
15, 20, 30, and
40mg caps
1mg/mL oral soln
>60kg: 40mg bid
<60kg: 30mg bid
None
Peripheral 
neuropathy
None
LAMIVUDINE
(3TC, Epivir)
150mg tabs 150mg
with AZT 300mg as
Combivir 10mg/mL
oral soln
150mg bid or with
AZT as Combivir 
(1 tab bid) 
<50kg: 2mg/kg bid)
None
(minimal toxicity)
None
ABACAVIR
(ABC, Ziagen)
300mg tabs
300mg bid
None
Alcohol #ABC levels
41%
Hypersensativity 
(2-5%), fever, 
nausea, vomiting,
anorexia, cough,
dyspena, malaise,
morbilliform rash.
May be life-threaten-
ing with rechallenge.
None
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Antiretroviral Agents Dosing and Administration Recommendations
NEVIRAPINE (Viramune)
200mg tabs
200mg po qd x 14 days,
then 200mg po bid
None
G Induces cytochrome
P450 enzymes• PI
interactions see Table 4-
16 in Bartlett Guide*
G Rash (15-30%) may
require hospitalization;
rare cases of 
Stevens-Johnson 
syndrome; hepatitis
DELAVIRDINE (Rescriptor)
100mg and 200mg tabs
400mg po tid
None
G Methadone AUC
decreased 60% titrate
methadone dose
G Not recommended:
Ketoconazole and rifampin
G Caution: anticonvulsants
G Rash; headches
G Increased transaminase
levels
EFAVIRENZ (Sustiva)
50, 100, 200mg caps
600mg po qd at hs
#50% with high fat meal; avoid after high fat meal
G Inhibits and induces cytochrome P450 3A4 enzymes
G Contraindicated drugs: astemizole, midazolam, triazolam, 
cisapride, ergot alkaloids, tergenadine
G Possibly important drug interactions: rifampin, rifabutin, 
clarithromycin, phenobarbitol, ethinyl estradiol, anticonvulsants, warfarin
G PI interactions: see Table 4-16 in Bartlett Guide*
G Methadone AUC decreased 60% titrate methadone dose
G Dizziness, "disconnectedness," somnolence, insomnia, bad dreams,
confusion, amnesia, agitation, hallucinations, poor concentration
G 40% usually resolves after 2 weeks
G take hs.
G Rash- severe in 5%; rare reports of Stevens-Johnson syndrome:
G Teratogenic in cynomalgus monkeys
G Avoid in pregnancy, and women and men should use adequate 
contraception methods.
G False positive drug screening test for cannabinoids (marijuana)
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Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
HIV101 continued on page 5
INDINAVIR
(Crixivan)
200, 400, 
333mg caps
800mg q 8h
Separated ddI 
dose by 1 hr
#77%; take 1 hr
before or 2 hours
after meals; may
take with low fat
snack or skim milk
GI intolerance
(10-15%);
nephrolithiasis or
nephrotoxicity
(10-15%);
headache;
asthenia;
dizziness; rash;
metallic taste;
ITP; alopecia;
lab: increase
indirect
bilirubinemia
(inconsequential)
Class side
effects*
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RITONAVIR
(Norvir)
100mg caps
600mg/7.5 mL po
soln
600mg bid Separate
ddI dose by 2 hr
#15%; take with
food if possible to
improve tolerability
GI intolerance (20-
40%); paresthesias-
circumoral and
extremities (10%);
taste perversion
(10%); lab:triglyc-
erides increase in
60% and transami-
nase increase in 10-
15%, CPK and uric
acid increase Class
side effects*
SAQUINAVIR
(Invirase)
200mg caps 
(Hard gel caps)
Not recommended
as single PI 400mg
bid with RTV
No food effect when
taken with RTV
GI intolerance  
(10-20%); increase
Class effects*
(Fortovase)
200mg caps 
(Soft gel caps)
1200mg tid
#6x; take with large
meal unless taken
with RTV
GI intolerance
(20-30%);
headache;
hypoglycermia;
transaminase
increase
Class side
effects*
NELFINAVIR
(Viracept)
250mg tabs 
50mg/g oral powder
1250mg bid or
750mg tid
#2-3x; take with
meal or snack
Diarrhea
(10-30%)
Class side
effects*
AMPRENAVIR
(Agenerase)
50, 150mg caps
15mg/mL
1200mg bid
high fat meal
decreases AUC
20%; can be taken
with or without food,
but high fat meal
should be avoided.
GI intolerance
(10-30%); rash
(20-25% - usually
at 1-10 wks),
Stevens-Johnson
syndrome (1%);
paresthesias
(10-30% -
perioral or
peripheral)
Increase in liver
function tests.
Class side
effects*
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*For drug interactions with PIs, see the December issue of HEPP News. For more info on class side effects see Table 4-16 from the reference for this
chart, Chapter 4 of Bartlett JG and Gallant JE.  2000-2001 Medical Management of HIV Infection.  Johns Hopkins University, Baltimore, MD. 2000.
The 40th Annual Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC) was held September 17-20, 2000 in
Toronto, Canada. What follows are brief comments on data present-
ed this year that may be clinically relevant to the care of HIV-infect-
ed inmates.
Pharmacokinetic Interactions
Information was presented concerning pharmacokinetic interactions
of dual protease inhibitor (PI) regimens and regimens containing
both a PI and an NNRTI. Notably, efavirenz decreases the
concentration of indinavir, lopinavir,  and amprenavir sufficiently to
raise concerns about sub therapeutic PI levels.  In these situations,
the use of low dose (100-200 mg p.o. bid) ritonavir can adequately
raise the levels of the second PI, usually without significant side
effects.  In the case of Kaletra, the dose should be increased from 3
bid to 4 bid (400/100g533/133) when efavirenz is co-administered.
Clearly, management of potential pharmacokinetic interactions is
becoming more complex and specialized.  Because incarcerated
patients move from facility to facility and encounter providers with
varying knowledge about doses of antiretroviral agents used in com-
bination, opportunities for prescription errors abound.  HEPP News
editors believe that each system should have in place a process of
routine review of medication regimens to guard against inadvertent
errors.  
Cases of Death in HIV infected patients
Over the past several years, it has been shown that the use of high-
ly active antiretroviral therapy has lead to decreased mortality and
drop in the incidence of new opportunistic infections. A study by
Jacobsen et al at Alta Bates Medical Center in California reviewed
the causes of death in 56 HIV infected patients who died in1998 and
1999.  This study revealed that over half (55%) died of liver disease,
cardiovascular disease, cancer, accidents, and other etiologies not
directly related to HIV. Similar tends are also being seen in the  the
correctional setting. In the California Department of Corrections’
Hospice Unit in Vacaville,  HIV is no longer  the most common admit-
ting diagnosis. At Vacaville,  HIV related deaths fell from 72 in 1995
to 12 in 1999, in spite of an increase in patient population This
serves as a reminder that as HIV becomes more of a chronic treat-
able illness, we must not lose sight of the routine medical care of our
HIV infected patients.
Antiretroviral Therapy Regimens
Data was presented this year showing comparable results between
NNRTI vs. PI based regimens.  Additionally, there is further evidence
supporting the use of single class regimens which include abacavir
ICAAC Update For The Correctional Provider
Continued on page 6
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as opposed to a PI or NNRTI.  These non-PI options may offer
enhanced tolerability and adherence, and perhaps less long term
side effects.  This data is tempered by some work suggesting that
NNRTI and single class regimens may not fare as well in the setting
of higher baseline viral loads (greater than 100,000).  Additionally,  a
UK study of 2,111 patients who were started on therapy and followed
for a median of 450 days showed that although PI and NNRTI regi-
mens both achieved viral loads of less than 500 in similar times,
NNRTI based combinations showed earlier rebound.  
The new PI Kaletra (co-formulated lopinavir-ritonavir), was the big
news this year, with data presented on its use in both salvage and
naïve settings. Kaletra performed impressively in naïve patients, with
over 80% of those treated maintaining a viral load of less than 400 at
24 weeks.  Even more impressively, however, an intent to treat analy-
sis of the use of Kaletra plus efavirenz plus 2 NRTIs in salvage ther-
apy for those who had failed 2 PIs but were NNRTI naïve yielded at
24 weeks 82% of patients with a viral load of less than 400.  The main
side effects were increased cholesterol and tryglicerides.  This regi-
men shows great promise in salvage therapy, while its role in initial
therapy has potential but must be further defined.
Work was presented this year demonstrating that in the setting of
virus highly resistant to AZT, hypersusceptibility to NNRTIs can
develop.  This may explain some of the benefit of the use of NNRTIs
in the salvage setting.  Other data demonstrated that virus with mul-
tiple PI resistance mutations is often less fit and therefore less able
to damage the immune system. This offers a rationale for continuing
treatment in those who are "failing therapy" (persistantly detectable
viral loads),  tolerating it without side effects, and for whom no other
regimens are available.
A study examined the prevalence of drug resistance in prisoners in
the Texas Department of Criminal Justice as compared to patients
seen at the University of Texas clinics.  This work demonstrated a
higher instance of some resistance patterns in prisoners and the
author suggested that this may be due to factors inherent in the cor-
rectional medical delivery system. It is important to note, however,
that the study did not mention whether the inmates were studied at
entry to prison.  The assumption appears to have been made that this
resistance developed while incarcerated, when in fact patients may
have presented to prison with more resistant virus.  Additionally, it
would be valuable to compare prisoners to a non incarcerated popu-
lation which is similarly matched for co-morbid mental illness and
substance abuse.
Lipid Abnormalities
Further evidence was presented concerning the increased incidence
of insulin resistance in patients receiving antiretroviral therapy as
demonstrated by fasting hyper-insulinemia and impaired oral glucose
tolerance testing. Insulin resistance is seen in patients receiving both
PI and non-PI regimens, and is associated with an increased risk for
cardiovascular events. Studies attempting to correct these abnormal-
ities by switching from a PI based regimen to an NNRTI or abacavir
based regimen have met with mixed success.  In patients who are
NNRTI naïve, viral load reductions are usually maintained when an
NNRTI is substituted for the PI.  A decrease in tryglicerides and
insulin resistance may be seen although total cholesterol may not
change. Usually there is also no change in lipodystrophy.  For those
considering a change to an abacavir regimen, it should be noted that
there is an increased risk of  virologic failure if there is extensive prior
treatment experience with AZT.
Opportunistic Infections
Cytomegalovirus (CMV)
More data was presented that CMV disease is unlikely to progress in
those whose CD-4 count has risen to >300 while on HAART. The risk
does exist however for the immune reconstitution syndrome, which
can include macular edema and may require steroid treatment.  In
those who have stopped treatment for active disease because CD4
counts rose to >300, the risk for reactivation of disease dramatically
increases again if CD4 falls <50.  For this reason, anti-CMV treat-
ment should be restarted presumptively in those whose CD4 declines
to <50/mm3.
Hepatitis C (HCV)
The United States Public Health Services (USPHS) and the
Infectious Disease Society of America consider HCV to be an HIV
related opportunistic infection,  In the United States, approximately
30% of those who are HIV infected are also infected with HCV.  Most
studies have demonstrated that HIV/HCV coinfected individuals
progress more rapidly to end state liver disease than do those who
are HCV infected but HIV negative.  The USPHS recommends that
all those who are HIV infected should be tested for HCV. All HCV
infected patients should be treated. This does not mean that every-
one should receive interferon, but treatment also includes patient
education, including alcohol abstinence and avoidance of illicit drugs
that may exacerbate liver disease.  Patients should be counseled on
methods to decrease transmission of HCV, and should be vaccinat-
ed for HBV and HAV if not already immune.  Lastly, careful attention
should be given to dose modifications of medications that are metab-
olized by the liver. As for treatment with interferon, there is little evi-
dence to support this practice in those with poorly controlled HIV dis-
ease especially if the CD4 count is less than 200-300.  In those with
higher CD4 counts, well controlled HIV viral loads, and the absence
of other contraindications, interferon with/without ribavarin may be
appropriate on a case by case basis.
Human Papillomavirus (HPV)
Data was presented demonstrating that HIV infected individuals are
more commonly infected with HPV, are on average infected with
more serotypes, have a greater incidence of clinically evident dis-
ease, and are more likely to have persistent HPV infection compared
to those who are not HIV infected.  Additionally the risk for invasive
disease is directly related to the decline in CD4 count.
Patients with Low Level Persistent HIV
Viremia
In spite of our best efforts, for some patients who do  not  maintain an
undetectable viral load there is no suitable salvage regimen avail-
able.  A study from Tenorio et al in Chicago compared three groups
of patients: 1) those who maintained an HIV VL <50, 2) those with
VLs that plateau at 50-10,000 and 3) those with VL>12,000.  Notably,
groups 1 and 2 had no difference in lymphoproliferative responses
nor in the incidence of opportunistic infections, while group 3 per-
formed worse in both areas.  CD4 increase were as follows: group 1>
group2> group 3.  It was also noted that group 2, with persistent low
level virema, developed less resistance mutations than did group 3.
This data is encouraging information for that group of patients who
plateau at a low but detectable viral load and for whom no other suit-
able regimens are available.
ICAAC Updates... (continued from page 5)
7Response by Frederick L. Altice, M.D.* :
In general, this is a healthy male with suppressed CD4 count and an
extremely high viral load who is at high risk for progression of HIV.
The first thing I would do is initiate PCP prophylaxis with TMP/SMZ.
The patient’s motivation makes initiation of antiretroviral therapy
somewhat easier than in a patient who is not convinced of the poten-
tial benefits of treatment.  One should next consider determining if
this patient has any of the four characteristics associated with an
increased risk for virologic failure of antiretroviral therapy (baseline
resistance mutations, CD4<200, HIV-1 RNA > 100,000, and non-
adherence). Since this patient appears to have seroconverted more
than seven years ago, the likelihood of baseline resistance is less-
ened and I would therefore not order a baseline HIV genotype.
Because this patient is antiretroviral naïve, I would plan ahead with
appropriate adherence counseling (enforcing the message that the
first shot is the best shot).  
I would investigate institutional barriers to receiving ARTs, and if pre-
sent, I might select agents to which mutations arise slowly (i.e. have
a high barrier to genetic mutations). For some ART agents (3TC and
NNRTIs) resistance can develop after a single mutation. Therefore,
if medline routinely requires a 30+ minute wait, if medline staff were
not skilled to ensure a complete regimen, or if a history of confisca-
tion of medications during strip searches for those with "Keep on
Person" therapy existed, I might  avoid medications with a low genet-
ic barrier to resistance in first line therapy such as 3TC and the
NNRTIs (such as efavirenz, nevirapine). Lastly, since this patient has
a high viral load and a reduced CD4 count, I am less enthusiastic to
treat with less potent agents. I would select a regimen with maximal
potency and minimal toxicity (see table 1). Irrespective of the anti-
retroviral combination, I would monitor LFTs carefully, given this
patient’s coinfection with HCV.
Based on clinical trials of individuals with HIV-1 RNA > 100,000, I
would avoid the use of nevirapine and triple nucleoside analogue
therapy.  Nearly any of the recommended nucleoside analogue com-
binations would be an acceptable initial treatment strategy.  I might
avoid the use of lamivudine (3TC) given this patient’s increased risk
for virological failure and the relative ease of developing resistance to
this agent.  I would also consider using any of a number of non-con-
ventional nucleoside combinations, particularly the use of abacavir
(ABC) as part of the nucleoside backbone (in combination with ZDV,
DDI or D4T) given its potency. The major caveat for this approach
would be if a system was not accustomed to managing the ABC
Hypersensitivity Syndrome (see HEPP News , April 1999).  In addi-
tion,  I would consider using either efavirenz or a potent protease
inhibitor. Though efavirenz would be easier to administer, there are
two issues that might make  efavirenz more appropriate at a later
time: 1) if there were barriers to adherence, resistance would devel-
op quickly if not taken consistently and leave the entire class of
NNRTIs unavailable for future options; and 2) recent data suggesting
hypersusceptability to NNRTIs (efavirenz, nevirapine) in patients with
genotypic mutations to NRTIs (AZT, 3TC, d4T, ddI, ABC) favors their
use as salvage therapy.  
Among the PIs, I would only consider those that are dosed twice
daily. This means using nelfinavir or amprenavir alone or pharmaco-
kinetic enhancement of saquinavir, indinavir or lopinavir with low
dose ritonavir (see Table 2) . Lopinavir is formulated with ritonavir as
kaletra; (see newsflashes, page 8). Ideally, among the protease
inhibitors, I would consider using nelfinavir upfront since data demon-
strates successful salvage therapy with other PIs in cases of nelfi-
navir failure. Additionally, nelfinavir’s diminished effect on cytochrome
P450 decreases the likelihood of drug interactions, and there is less
hyperlipidemia associated with nelfinavir compared to some other
PIs. The benefit of the pharmacokinetic enhancement of the PIs has
not been thoroughly studied in comparison trials of other PIs, how-
ever is likely to have improved efficacy and potentially increased tox-
icity compared to non-enhanced use of a PI. 
Lastly, because this patient has an increased risk for virologic failure,
I would order a viral load every four weeks until the patient achieves
a viral load (VL) of <50 copies/mL (ultrasensitive assay). If the patient
failed to achieve a decrease in viral load of at least one log (90%) by
four weeks, VL<400 copies by 12 weeks or < 50 copies by 24 weeks,
I would consider intensification therapy using an additional agent if
adherence was not the reason for virological failure. (See HEPP
News, October 1999)
EFFECT
IDV-  #2-5x
RTV- no change
NFV- 1.5x
RTV- No change
APV- #2.5x
RTV- no change
SQV- #2x
RTV- No change
RECOMMENDATIONS
IND 400mg bid + RTV 400mg
bid or IDV 800mg + RTV 100-
200mg bid
RTV 400mg bid + NFV 500-
750 bid
APV 1200mg qd + RTV 200mg
qd or APV 600mg bid + RTV
100mg qd. With EFV/APV/RTV
use: RTV 200mg bid, APV
1200 mg bid + EFV 600mg hs.
SQV 400mg bid + RTV 400mg
bid
DRUG
Indinavir (IDV)
Nelfinavir (NFV)
Amprenavir (APV)
Saquinavir (SQV)
Table 2. Dosages for Regimens with Ritonavir + Other 
Protease Inhibitor
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MP is a 36-year-old African American male, newly diagnosed with HIV infection, whose CD4 lymphocyte count is 146 (10%) and HIV-
1 RNA level is 122,000 copies/mL. His last HIV risk behavior was seven years ago when he injected drugs. He has been incarcerated
for the past four years and reports no HIV risk behavior within prison. He has had no major illnesses and has no abnormalities on
physical exam. Family history is significant for hypertension and CVA, but not for diabetes.  He is immune to HBV (HBSAg negative)
and is HCV antibody positive (HCV Ab positive).  His CBC is normal and his hepatic transaminases are mildly elevated with an
AST=66 and ALT=74. His lipids are within normal limits.  The patient is extremely interested in starting antiretroviral therapy.  What
are the considerations for initiating antiretroviral therapy in this inmate who has two remaining years to his prison sentence?
Ask the Expert: Initiating HAART
Adapted from Bartlett JG and Gallant JE.  2000-2001 Medical Management
of HIV Infection.  Johns Hopkins University, Baltimore, MD. 2000.
[D4T (stavudine)or ZDV (zidovudine)] + DDI (didanosine) + NFV
(nelfinavir)
(D4T or ZDV) + ABC (abacavir) + NFV
(D4T or ZDV) + DD I + EFV (efavirenz)*
(D4T or ZDV) + ABC + EFV*
*EFV containing regimens have been demonstrated to have similar
efficacy for patients with VL greater and less than 100,000 copies.
Enthusiasm for its use is tempered in some systems, which 
inefficient medication administration may increase risk of poor
adherence. Resistance is more likely to develop in the presence 
of NNRTIs if adherence is poor.
Table 1. Examples of Initial HAART Regimens
*Speakers Bureau:  Agouron Pharmaceuticals, Bristol-Myers Squibb,
DuPont, Glaxo Wellcome, Merck, Roche.
High Rates of Hepatitis C in Massachusetts
State Prisons
A blind test conducted last spring found that
29% of men and 39% of women in the
Massachusetts’ prison system have hepatitis
C, while 4% of the state’s inmates have tested
positive for HIV. Since Massachusetts prisons
are forbidden to routinely test for either HIV or
hepatitis C, most inmates who do not request
screening remain undiagnosed. (Contrada,
Springfield Union-News, 9/25/00).
New PI Combo: Kaletra
Sharon Walmsley of the University of Toronto
reported the results of a phase II, multi-center,
international double-blind study of 653 ART-
naive subjects treated with either ABT-378/r
(Kaletra) or nelfinavir in combination with
nucleoside analogues. The results, reported at
ICAAC last month, indicated that plasma HIV
in the bloodstream dropped to undetectable
levels in 79% of the patients taking Kaletra-
based combination therapy versus participants
receiving nelfinavir-based combination therapy
for 40 weeks. Walmsley said she believes the
easier dosing schedule and longer half-life of
Kaletra, which combines lopinavir and riton-
avir, were two factors in the better results, as
patients were not only more compliant with
Kaletra but the drug stayed longer in the body
if they skipped a pill. (Walmsley S, Badley A,
Beall G, et al. ICAAC 2000, Abstract #693).
FDA Approves Enteric Coated 
Didanosine (Videx)
On October 31, the Food and Drug
Administration approved enteric-coated
didanosine (ddI; Videx). This new formulation
of Videx includes delayed-release capsules
that contain enteric-coated "beadlets," which
allow slow release of the drug into the blood-
stream over a 24-hour period. Enteric-coated
didanosine may be useful for HIV-infected
patients who show intolerance of the current
"buffered" tablet formulation of Videx, which
frequently causes diarrhea.  For more informa-
tion, contact: John Kouten, 609-897-2637 or
john.kouten@bms.com. (BMS Press Release,
10/31/00.  Also see http://www.fda.gov/cder/).
Staggering Numbers: AIDS Deaths in South
African Prisons
AIDS-related deaths in South African prisons
account for as much as 90% of the 1,000 nat-
ural deaths in South Africa this year.  Since
1995, AIDS-related deaths in South African
prisons have risen 300%. Gideon Morris, sec-
retary of the Office of the Inspecting Judge,
South Africa, attributes this increase in deaths
to high incidence of rape and increasing num-
ber of inmates with HIV infection. (Agence
France Presse, 10/17/00. www.afp.com).
HIV Among Prison Inmates in Russia
Approximately 700 HIV-infected patients
reside in the Kaliningrad regional penal sys-
tem in Russia. There are 46,000 registered
AIDS cases nationwide, Russian Health
Ministry statistics show; however, WHO offi-
cials say the actual number could be 10 times
higher. The inmates are given a special diet to
help them stay strong against HIV, but
Western AZT-type drugs that boost the
immune system are too costly, and the prison-
ers often must make do as best they can.
(Ittner, Phil. San Francisco Chronicle,
10/16/00. P. A11; www.sfgate.com)
Request for Proposals (RFP): 
Equal Access Initiative- Computer
Grants Program 2000/2001.
Due Date: December 1, 2000
100 minority community-based
HIV/AIDS organizations will lreceive
access to the Internet through a unique
in-kind computer grants program.
Contact: National Minority AIDS Council
(NMAC) at 202.483.6622 
or info@nmac.org
Visit: www.nmac.org/pubs/
RFP2000-2001.htm
National STD Prevention Conference
December 4-7, 2000
Milwaukee, WI  
Contact: Glenda Vaughn, Centers for
Disease Control and Prevention 
Call: 404.639.1806 
E-mail: ghv1@cdc.gov 
Medical Management of AIDS: A
Comprehensive Review of HIV
Management - Winter Symposium
December 7-9, 2000
San Francisco, CA
Contact: Cliff Brock
Department of Medicine UCSF
Call: 415.476.5208
Fax: 415.476.3542
Email: cme@medicine.ucsf.edu
Visit: http://medicine.ucsf.edu/
programs/cme
2001 ACA Winter Conference 
January 22-24, 2001
Nashville, Tennessee 
Call 1-800-222-5646, ext. 1922 
Fax: 1-301-918-1900
Visit: www.corrections.com/aca
8th Conference on Retroviruses and
Opportunistic Infections
February 4 -8, 2001
Sheraton Chicago Hotel and Towers,
Chicago, IL
Call:  703.535.6862
Fax: 703.535.6899
E-mail: info@retroconference.org
Visit: www.retroconference.org
Call for Abstracts: 13th National
HIV/AIDS Update Conference
March 20-23, 2001
San Francisco CA
Abstract Deadline:  
December 15, 2000
Call: 212.806.1633
Fax: 212.806.1608
Email: jennifer.attonito@amfar.org
Visit: www.amfAR.org
Save the 
Dates
News Flashes
Office for Human Research Protections
(OHRP) (formerly Office for Protection from
Research Risk , OPRR)
http://ohrp.osophs.dhhs.gov/
HIV/AIDS Sites:
CDC AIDS Clearinghouse
www.cdcnpin.org
DHHS Treatment Guidelines
www.hivatis.org
HIV and Hepatitis
www.hivandhepatitis.org
HIV InSite
www.ucsf.edu/medical
Johns Hopkins AIDS
http://hopkins-aids.edu
Medscape
http://medscape.com
Human Subject Research Sites:
OHRP: Prisoners as Subjects
http://ohrp.osophs.dhhs.gov/humansubjects/
guidance/prison.htm
http://ohrp.osophs.dhhs.gov/polasur.htm
The New England Journal of Medicine --
September 14, 2000 -- Vol. 343, No. 11
Protecting Research Subjects -- What Must
Be Done
www.nejm.org/content/2000/0343/0011/0808.asp
Web Resources
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Correction: Fax-back Survey
On Monday, November 6, HEPP News
subscribers received a fax-back survey to
provide us feedback on the newsletter.
We incorrectly listed Agouron as our sole
sponsor. HEPP News is extremely grate-
ful for the support provided through
Abbott, Bristol Myers-Squibb, Dupont,
Glaxo, Merck, Roche, and Roxane, as
well as Agouron. Due to the generousity
of our sponsors, HEPP News is able to
be the only independent newsletter avail-
able to correctional health care providers
caring for HIV-infected prison and jail
inmates.
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
Dec. 31, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Which of the following combinations would be appropriate for
starting a treatment-naïve patient on ART?
a) Stavudine (d4T) + abacavir (ABC) + nelfinavir (NFV)
b) Zidovudine (ZDV) + didanosine (ddI) + nelfinavir (NFV)
c) Stavudine (d4T) + abacavir (ABC) + efavirenz (EFV) (in a 
setting with an excellent medications administration system)
d) All of the Above
e) None of the Above
2. Which of the following statements is false?
a) Pre-trial detainees have a legal right to health care 
because of the "due-process" clause of the 14th 
Amendment.
b) According to Supreme Court case law, prison officials are 
responsible for providing "adequate food, clothing, shelter, 
and medical care."
c) Circuit and district courts have uniformly interpreted 
"adequatemedical care" to include access to Protease 
Inhibitors.
3. In which of the following settings has Kaletra (lopinavir-
ritonavir) been shown to be successful?
a) In treatment-naïve patients
b) In salvage regimens where the patient was failing 
NNRTIs.
c) In salvage regimens where the patient was failing 2 PIs.
d) A and C
e) All of the above.
4. Which of the following statements is false?
a) Between 1998 and 1999, over half of the HIV deaths at 
one facility in California were due to liver disease, 
cardiovascular disease, cancer, accidents, and other 
etiologies not directly related to HIV.
b) New data shows that strains of HIV with multiple PI 
resistance mutations are often less fit and therefore less able
to damage the immune system. In patients who are 
failing therapy but tolerating the regimen without side effects,
clinicians may want to continue the same PI-regimen.
c) Anti-CMV treatment should be restarted presumptively in 
those HIV patients whose CD4 was above 300/ mm3 but has
declined to <50/mm3.
d) All of the above
e) None of the above
5. Efavirenz decreases the concentration of which of the 
following PIs sufficiently to raise concerns about sub-therapeutic
PI levels?
a) Indinavir 
b) Lopinavir 
c) Amprenavir 
d) All of the above
e) None of the above.  EFV has no such effect.
6. According to data presented at ICAAC, which of the following
statements about HPV in HIV-infected persons is false?
a) They are more commonly infected with HPV.
b) They are on average infected with more serotypes of HPV
c) Their risk for invasive disease is not directly related to the 
decline in CD4 count.
d) They have a greater incidence of clinically evident HPV 
disease. 
e) They are more likely to have persistent HPV infection 
compared to those who are not HIV infected.
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HIV 101 5  4  3  2  1   5  4  3  2  1   
Ask the
Expert 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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